[Therapeutic cancer vaccination for treatment of haematological cancers]

Autor: Mo, Holmström, Jh, Grauslund, Ng, Dahlager-Jørgensen, Klausen U, Hc, Hasselbalch, Mads Hald Andersen

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::57d5c3bbf24d7938bfc351a1d487fc06
http://europepmc.org/abstract/med/31610839

The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling.

Autor: Perez-Penco M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Byrdal M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Lara de la Torre L; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Ballester M; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Khan S; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Siersbæk M; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark., Lecoq I; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; IO Biotech ApS, Copenhagen, Denmark., Madsen CO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hansen M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Johansen JS; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Olsen LR; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark., Grøntved L; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark., Chen IM; Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Arnes L; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Holmström MO; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Andersen MH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Mads.Hald.Andersen@regionh.dk.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. Mads.Hald.Andersen@regionh.dk.

Publikováno v: Cellular & molecular immunology [Cell Mol Immunol] 2024 Dec 09. Date of Electronic Publication: 2024 Dec 09.

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Autor: Hasselbalch HC; Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark., Junker P; Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark., Skov V; Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark., Kjær L; Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark., Knudsen TA; Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark., Larsen MK; Department of Hematology, Zealand University Hospital, 4000 Roskilde, Denmark., Holmström MO; National Center for Cancer Immune Therapy, Herlev Hospital, 2730 Herlev, Denmark., Andersen MH; National Center for Cancer Immune Therapy, Herlev Hospital, 2730 Herlev, Denmark., Jensen C; Nordic Bioscience A/S, 2730 Herlev, Denmark., Karsdal MA; Nordic Bioscience A/S, 2730 Herlev, Denmark., Willumsen N; Nordic Bioscience A/S, 2730 Herlev, Denmark.

Publikováno v: Cancers [Cancers (Basel)] 2023 Aug 29; Vol. 15 (17). Date of Electronic Publication: 2023 Aug 29.

Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer.

Autor: Grützmeier SE; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark., Kovacevic B; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark.; Department of Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Vilmann P; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark., Rift CV; Department of Pathology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Melchior LC; Department of Pathology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Holmström MO; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark., Brink L; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark., Hassan H; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark., Karstensen JG; Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.; Pancreatitis Centre East, Gastroenterology Unit, Copenhagen University Hospital-Amager and Hvidovre, 2650 Hvidovre, Denmark., Grossjohann H; Department of Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Chiranth D; Department of Pathology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Toxværd A; Department of Pathology, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark., Hansen CP; Department of Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Høgdall E; Department of Pathology, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark., Hasselby JP; Department of Pathology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark., Klausen P; Gastro Unit, Endoscopic Division, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, Denmark.; Department of Pathology, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jul 19; Vol. 15 (14). Date of Electronic Publication: 2023 Jul 19.

First in man study: Bcl-Xl_42-CAF ^® 09b vaccines in patients with locally advanced prostate cancer.

Autor: Mørk SK; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kongsted P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Westergaard MCW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Albieri B; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Granhøj JS; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Donia M; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Martinenaite E; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; IO Biotech Aps, Copenhagen, Denmark., Holmström MO; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Madsen K; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kverneland AH; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Kjeldsen JW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Holmstroem RB; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Lorentzen CL; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Nørgaard N; Department of Urology, Copenhagen University Hospital, Herlev, Denmark., Andreasen LV; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Wood GK; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Christensen D; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark., Klausen MS; EVAXION BIOTECH A/S, Hørsholm, Denmark., Hadrup SR; Department of Health Technology, Technical University of Denmark (DTU), HEALTH TECH, Kongens Lyngby, Denmark., Thor Straten P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Andersen MH; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Svane IM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Mar 14; Vol. 14, pp. 1122977. Date of Electronic Publication: 2023 Mar 14 (Print Publication: 2023).